Do you like thinking about scientific problems and finding solutions to pressing clinical needs or vexing biological questions? Have you imagined solving important problems as opposed to merely difficult ones? Then this position might be for you!
My lab at Sloan Kettering Institute focuses on the development of novel and innovative molecular imaging approaches for cancer diagnostics. Our approaches combine and utilize cutting-edge biology, nanotechnology, chemistry, and physics to create novel imaging and therapy paradigms that enable much earlier detection and improved therapy monitoring for patients with cancer.
In particular, we are looking for talented and motivated individuals to investigate tumor neovasculature using photoacoustic imaging. This research project focuses on the expression of a specific protein on tumor neovasculature, which we are interrogating with a tumor-on-a-chip system and a prototype photoacoustic scanner, which allows for high-resolution in vivo imaging of vasculature. We aim to define biology in tumor vasculature and its suitability as a target for novel tumor therapies. This project is a collaboration with the Helmholtz Institute in Munich, Germany and the Weizmann Institute in Rehovot, Israel and is funded through the NCI.
An ideal candidate is a highly motivated PhD graduate with experience in imaging (optical/photoacoustic), and is eager to bring in his/her expertise as well as ideas and can think out of the box. Excellent communication and experimental skills are essential.
Memorial Sloan Kettering Cancer Center in New York City is the world’s oldest and largest private institution devoted to the prevention, treatment, and cure of cancer. We fulfill our mission—the progressive control and cure of cancer through programs of patient care, research, and education—by facilitating collaborations among scientists and clinical specialists, enabling new discoveries and the development of new treatments.
Please send a cover letter that describes your research interests, CV, and three letters of reference to Jan Grimm, MD, PhD at the Molecular Pharmacology Program, Sloan Kettering Institute at email@example.com.